Background: miRNAs have been implicated in numerous tumorigenic pathways, and previous
Introduction
The 1993 discovery of lin-4 in C. elegans brought about a fundamental change in the understanding of how gene activity is regulated, helping to uncover an additional element of the central dogma of molecular biology. The 22-nucleotide lin-4 transcript, with its posttranscriptional gene regulatory capacity, became the first identified member in what would later be the microRNA (miRNA) family of small non-protein-coding RNAs (1) . Since this initial discovery, more than 1,900 mature miRNAs (miRBase 18) have been experimentally verified in humans, regulating the activity of perhaps more than a third of all human genes (2, 3) .
The role of miRNA in tumorigenesis has been extensively studied in recent years. For example, miRNAs are commonly located within fragile sites on chromosomes (4) and act as both oncogenes and tumor suppressors (5, 6) . Further findings have shown that a global reduction in miRNA processing promotes carcinogenesis, and miRNA profile data have been successfully applied to classify tumors and predict prognosis in several cancer types (7) (8) (9) (10) . In addition, epidemiologic and experimental findings have implicated a role for miRNAs in virtually every human cancer. Previously, our group performed a survey of miRNA-related SNPs, followed by a genetic association study and functional analysis in breast cancer (11) . We identified miR196a-2 as a potential breast cancer-relevant miRNA, which is consistent with later findings implicating its tumorigenic relevance in other cancer types (12) (13) (14) . While a miR-202-associated SNP was identified in our survey, it was not associated with breast cancer risk in our population (11) . However, prediction algorithms such as TargetScan (15) several cancer types such as breast (9) , cervical (16), colorectal (17) and gastric tumors (18).
Interestingly, a recent miRNA profiling experiment comparing FL tumor cells to follicular hyperplasia cells identified a 44-miRNA signature of FL, which included miR-202 (19) .
Like many miRNAs, miR-202 is located within a chromosomal fragile site, in the subtelomeric region of chromosome 10, the deletion of which has been associated with endometrial (20) and brain tumors (21) , as well as developmental issues in children, including hyperactivity (22) and speech delay (23) . A recent study also found that miR-202 may negatively regulate the expression of the proto-oncogene, MYCN, resulting in the inhibition of neuroblastoma cell proliferation (24) .
In the current study, we experimentally identified the miR-202 targetome using a RIPChip-based approach. Functional interactions between identified targets were then investigated for disease-relevance using the Ingenuity Pathway Analysis tool. We also performed a population-based genetic association analysis of a polymorphism within the miR-202 stem-loop sequence and risk of non-Hodgkin lymphoma. In vitro gain-of-function experiments were further conducted to elucidate the functional significance of the variant.
Materials and Methods

Cell culture and miRNA transfection
HeLa cells were cultured in (+)-glutamine RPMI 1640 supplemented with 10% heatinactivated fetal bovine serum and 1% penicillin/streptomycin (Invitrogen, Carlsbad, CA).
Oligonucleotide transfection efficiencies were determined by fluorescence microscopy using the 
RIP-Chip analysis for miR-202 target identification
Ribonucleoprotein IP was performed using the RIP-Assay kit for microRNA (MBL) according to the protocol described by the manufacturer. Briefly, anti-EIF2C2/Ago2 monoclonal antibody (Novus Biologicals, LLC) was incubated with Protein G plus agarose beads (Pierce) at 4°C overnight to prepare antibody-immobilized beads. 20 million cells were harvested and washed four times with ice-cold DEPC-treated PBS. The cell pellet was lysed with 500 μl of lysis buffer and the supernatant was incubated with Protein G agarose beads without antibody to reduce nonspecific adsorption. The cell lysate was then transferred into a tube containing antibody-immobilized Protein G agarose beads and incubated for 3 hours at 4°C. The complex was washed five times with wash buffer prior to total RNA isolation. Mouse IgG1 isotype control (Novus Biologicals, LLC) was used as a negative control for the IP procedure. In order to confirm proper functioning of the RIP assay, an aliquot of precleared cell lysate, post-IP beads, and the flow-through fraction of antibody-immobilized Protein G agarose beads-RNP complexes were used for analysis of Ago2 quantity by Western blot. For use in the Western blot, mouse anti-EIF2C2/Ago2 monoclonal antibody was diluted 1:500 and chicken anti-mouse IgG conjugated with HRP was diluted 1:2000. SuperSignal West Pico Chemiluminescent Substrate (ThermoScientific, Rockford, USA) was used for visualization.
Genome-wide expression levels were analyzed in total RNA samples from total cell lysate and antibody-immobilized Protein G agarose beads-RNP complexes from cells transfected with miR-202 mimic or negative control using the Agilent 44K 60-mer human whole-genome microarray. Signal hybridization and scans were performed by MOGene, LC (St Louis, MO).
The normalized signal intensities of probes from RNP-bead complexes (IP fraction) were divided by the signal intensities from total cell lysate (pre-IP fraction) in miR-202 mimic-transfected cells. Transcripts were identified as members of the global miRNA targetome if they exhibited an enrichment fold change > 2.0. From this list, IP to pre-IP signal intensity ratios in miR-202 mimic-transfected cells were divided by IP to pre-IP signal intensity ratios in NC cells.
Transcripts exhibiting normalized signal ratios of > 1.5 were considered to be bound with miR-202 in the RNA-induced silencing complex (RISC), and therefore potential direct miR-202 targets. All microarray data were uploaded to the Gene Expression Omnibus database (accession # GSE42981).
Target screening
Enriched transcripts were screened for potential 3' UTR miR-202 binding sites using four 
NHL study population
The study population, which consists of female residents of Connecticut, has been described in detail elsewhere (30) . Briefly, 455 cases were identified through Yale Cancer Following the interview, each participant provided a 10 ml peripheral blood sample from which genomic DNA was isolated.
Genotyping of SNP rs12355840 in the stem-loop of miR-202
The SNP (rs12355840) was identified using the miR-202 sequence and location data in Duplicate samples from 100 study subjects and 40 replicate samples from each of two blood donors were interspersed throughout each batch, and the concordance rates for QC samples was >99%. All genotyping scores, including quality control data, were re-checked by different laboratory personnel and the assay accuracy was confirmed. The secondary structure of miR-202 was predicted using the Vienna RNAfold prediction algorithm (31) .
Statistical analysis of genetic association
All statistical analyses were performed using the SAS statistical software, version 9.1 (SAS Institute, Cary, NC), unless otherwise noted. For the case-control analyses, the allelic distribution of the SNP was tested in control subjects by goodness-of-fit Chi-square for compliance with Hardy-Weinberg equilibrium (HWE), and no departure from equilibrium was detected (P=0.930). Odds ratios and 95% confidence intervals were determined by unconditional 
Construction of the precursor miR-202 expression vector
Pre-mir-202-G and pre-mir-202-A constructs, consisting of the precursor miRNAs and a flanking region (299 bp on the left and 269 bp on the right), were synthesized using genomic DNA from individuals known to be homozygous for either the G or A allele of SNP rs12355840.
Each construct was cloned into a pMIRNA1 lentivector containing a green fluorescent protein marker (System Biosciences). Vectors were then sequenced to verify the accuracy of the inserts and subsequently transfected into HeLa cells using the Lipofectamine 2000 transfection reagent (Invitrogen). Transfection efficiency was verified by fluorescence microscopy.
RNA isolation and miR-202 detection
Total RNA from precursor mir-202-G-and mir-202-A-transfected HeLa cells were isolated using the miRNeasy Mini Kit (QIAGEN) with on-column DNA digestion. Sequences for the forward and reverse primers used to detect mir-202 precursors were 5'-CCTCCCAGGCTCACGAGGCT-3' and 5'-GGTGCAGGTGCACTGGTGCA-3', respectively.
Relative RNA abundance with respect to untransfected HeLa cells was assessed using the 2 -∆∆Ct method with RNA content normalized to the housing keeping gene HPRT1. To determine levels of mature miRNA, polyadenylated mature miRNA sequences were first generated and converted to cDNA using the NCode miRNA First-Strand cDNA Synthesis Kit (Invitrogen). The cDNA was then amplified using a custom miR-202-specific forward primer ( 
Luciferase target confirmation in Farage cells
Confirmation of miR-202 targets in the Farage lymphoma cell line was performed using the two luciferase-3' UTR constructs previously used for target-confirmation in HeLa cells. hours prior to evaluation in the luciferase assay, as described above, and an anti-miR-202 inhibitor:negative control luciferase signal intensity ratio was calculated for each gene. 
miR-202 targetome identification by RIP-Chip assay
Since miRNA function is mediated by argonaute (Ago) proteins in the RNA-induced silencing complex (RISC), co-immunoprecipitation of Ago with miRNA/mRNA complexes can be used to identify probable direct miRNA targets. First, we used an anti-Ago2 antibody to isolate global miRNA targets from HeLa cells (low expression of miR-202), which we identified using a genome-wide comparative hybridization microarray. Transcripts which were significantly enriched in the Ago2 antibody-treated fraction relative to total cell lysate (> 2.0x Table   2 ).
Validation of miR-202 target genes by luciferase reporter assay
To confirm that the RIP-Chip approach provides valid candidates for the miR-202 targetome, we selected, at random, HAS2 and FAM135A, for further validation using a 3'UTR Table 4) .
Lymphoma-related interaction network formed by identified miR-202 targets
Population-based genetic association
We further investigated miR-202's potential relevance in lymphomagenesis using human samples. A previous in silico analysis identified a SNP (rs12355840) located within the precursor region of miR-202 (11), which we genotyped in a population-based case-control study of nonHodgkin lymphoma (NHL) conducted in Connecticut (N=455 cases; 527 controls). Selected participant demographics and case pathology information for this population are presented in Table 5 .
Supplementary
Functional effect of SNP rs12355840 on miR-202 levels in vitro
As SNP rs12355840 is located within the stem-loop sequence of the miR-202 precursor (Fig. 4) , it may influence miR-202 levels in vivo by interfering with the formation of the secondary structure and/or affecting the processing of the pre-miRNA to its mature form. To test 
Luciferase miR-202 target confirmation in the Farage lymphoma cell line
Real-time RT-PCR revealed endogenous miR-202 levels to be 3.5-fold and 3.4-fold higher in Farage and Toledo B lymphoma cell lines, respectively, compared to levels in HeLa cells (data not shown). In order to validate our assumption that miR-202 targets are conserved between HeLa and B lymphocytes and investigate the endogenous functionality of miR-202 in lymphoma, we reaffirmed the target status of HAS2 and FAM135A in the Farage lymphoma cell line using luciferase-3' UTR constructs and anti-miR-202 inhibitors. As expected, inhibiting miR-202 resulted in an increase in luciferase signal intensity for both HAS2 (2.5-fold) and FAM135A (3.1-fold) relative to negative controls (Fig. 5C ).
Discussion
Our RIP-Chip analysis of direct miR-202 targets identified several transcripts with potential relevance for lymphoma-related processes, and the gene interaction network most strongly associated with the potential targets contained several molecules with known involvement in lymphomagenesis. Examples include: suppressor of cytokine signaling (SOCS1), a tumor suppressor (32) and potential miR-202 target that is epigenetically silenced in some Bcell lymphomas (33) , and B2M, a subunit required for major histocompatibility complex (MHC) class I assembly that is frequently mutated in NHL (34, 35) . Perhaps most interestingly, DICER1 was identified as a potential miR-202 target. According to TargetScan, the DICER1 3'UTR contains three conserved miR-202 binding sites. This protein is essential for the biogenesis and proper function of all miRNAs, and thus has widespread biological importance (36) . Haploinsufficiency of DICER1 has been linked to susceptibility to multiple nonhematopoietic tumors (37, 38 Another important miR-202 target is the cell cycle regulatory element and protooncogene SKP2. This protein regulates the G1-S transition and encourages cell proliferation through the degradation of the cyclin-dependent kinase inhibitor p27 (40) . SKP2 was shown to be causally involved in lymphomagenesis (41) . In addition, inhibition of SKP2 in lymphoma cells leads to decreased growth and induces apoptosis, suggesting that SKP2 may be a potential target for therapeutic intervention in lymphoma patients (42) . Indeed, bortezomib, which operates in part by degrading SKP2(43), was recently approved by the FDA for the treatment of refractory multiple myeloma and mantle cell lymphoma (44) .
The results of our network-based analysis were consistent with the finding of a significant association between a SNP within the miR-202 stem-loop sequence and lymphoma in our NHL study population. Altogether, these finding suggests that rs12355840 may represent a novel risk biomarker for follicular lymphoma, and implicate miR-202 in follicular lymphomagenesis. Interestingly, the risk allele for rs12355840 (G) in our population-based genetic association analysis was shown to be associated with diminished pre-miR-202 processing capacity, and thus reduced mature miR-202 levels. Since both target genes DICER1 and SKP2 are lymphoma related, individuals harboring the risk allele for rs12355840 may have increased levels of both of these genes, which, in both cases, would be consistent with increased lymphoma analysis. For example, the genomic region harboring miR-15a and miR-16 has been found to be commonly deleted in B-cell chronic lymphocytic leukemias (45) , while a polycistronic miRNA cluster, miR-17-92, was found to be significantly amplified in B-cell lymphomas (46) . In addition, miR-21 induction has been found to be sufficient to cause lymphoma in mouse models (6) . Perhaps most the most relevant analysis comes from a recent miRNA profiling experiment comparing FL tumor cells to follicular hyperplasia (19) . These investigators describe a FL signature comprised of three groups of miRNAs: 1) increased in FL; 2) increased in most FL, but decreased in a subset of FL; and 3) decreased in FL. miR-202 was one of only 11 miRNAs belonging to Group 3, lending further support to our hypothesis that miR-202 may operate as a tumor suppressor in FL.
It should be noted that, apart from FL, our genetic association data were not significant for any other lymphoma subtype, a pattern which is consistent with the results from previous NHL genetic association analyses, including two recent genome-wide association studies (47, 48) and a large pooled case-control analysis (49) heterogeneity among NHL subtypes, which identified no significant risk factors which were unique to FL alone (50) .
As the RIP-Chip assay was conducted using HeLa cells, our analysis was limited to only those genes with detectable levels of endogenous expression in this cell model. As such, it is certain that a portion of the miR-202 targetome remains unelucidated. Moreover, HeLa cells may have a gene expression program that differs from that which would be seen in lymphoma.
Nonetheless, the fact that we were able to reaffirm HAS2 and FAM135A as miR-202 targets in In summary, we identified 141 potential members of the miR-202 targetome.
Interrogation enriched transcripts using miRNA target prediction algorithms revealed that a majority harbored predicted 3' UTR miR-202 binding sites. Potential targets were then investigated for disease-relevance using a network-based analytical approach. We discovered that a large proportion of the molecular interactions between identified targets were relevant to lymphomagenesis and hematopoietic processes. We also investigated whether genetic variants within the miR-202 stem-loop could account for differences in susceptibility to lymphoma in a population of NHL patients. A miR-202 precursor SNP, rs12355840, was found to be significantly associated with follicular lymphoma. These findings need to be further confirmed in studies with larger sample sizes and expression levels of miR-202 and identified targets need to be examined in lymphoma clinical samples. A functional analysis of this polymorphism demonstrated that the risk allele was also associated with reduced pre-miR-202 processing capacity, which is consistent with the findings of our network analysis. Taken together, these findings suggest a role for miR-202 in lymphomagenesis and the full extent of miR-202's role in lymphoma-related processes should be the focus of future investigations. 
